Press release
Hepatic Tumor Treatment Drugs, Clinical Trials, Pipeline Insights, and Companies 2024
Explore our latest breakthroughs in Hepatic Tumor Research. Learn more about our innovative pipeline today! @ Hepatic Tumor Pipeline Outlook [https://www.delveinsight.com/sample-request/hepatic-tumor-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]
Key Takeaways from the Hepatic Tumor Pipeline Report
* In September 2024:- Biotheus Inc.- A Phase Ib/II Clinical Trial to Evaluate the Preliminary Efficacy, Safety and Pharmacokinetics of PM8002 Injection Combined With PM1009 Injection in Patients With Locally Advanced or Metastatic Hepatocellular Carcinoma.
* In September 2024:- AstraZeneca- The purpose of this study is to measure the efficacy and safety of durvalumab intravenous (IV) solution plus bevacizumab IV solution after transarterial radioembolization (Yttrium 90 glass microspheres TARE) in participants with unresectable hepatocellular carcinoma (HCC) amenable to embolization.
* DelveInsight's Hepatic Tumor pipeline report depicts a robust space with 75+ active players working to develop 75+ pipeline therapies for Hepatic Tumor treatment.
* The leading Hepatic Tumor Companies such as Can Fite Biopharma, MiNA Therapeutics, Medivir AB, Janssen Research & Development, LLC, Etnova Therapeutics Corp., SillaJen Biotherapeutics, Akeso Biopharma, Shanghai Junshi Biosciences, Genmab/Janssen Biotech, Bio-Thera Solutions, Ocuphire Pharma, Surface Oncology, Genoscience, Onyx Pharmaceuticals, Qurient Co., Ltd., Kowa Company, Ltd., Eureka Therapeutics Inc., and others.
* Promising Hepatic Tumor Therapies such as Atezolizumab, Bevacizumab 15 mg/kg, Tiragolumab, Zimberelimab, Domvanalimab , and others.
Stay informed about the cutting-edge advancements in Hepatic Tumor Treatments. Download for updates and be a part of the revolution in cancer care @ Hepatic Tumor Clinical Trials Assessment [https://www.delveinsight.com/sample-request/hepatic-tumor-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]
Hepatic Tumor Emerging Drugs Profile
* Namodenoson: Can Fite Biopharma
Namodenoson is a small molecule A3 adenosine receptor (A3AR) agonist. It is an oral drug currently being developed for the treatment of oncology diseases including advanced liver cancer(hepatocellular carcinoma), pancreatic cancer and metabolic associated steatohepatitis (MASH). Currently it is in Phase III stage of clinical trial evaluation to treat Hepatocellular Carcinoma.
* MTL CEBPA : MiNA Therapeutics
MTL-CEBPA is a novel medicine being developed as a combination therapy in cancer. MTL-CEBPA is designed to reduce immune suppression of myeloid cells by restoring C/EBP-a protein to normal levels using the RNA Activation mechanism. The drug candidate uses the RNA interference mechanism of action. Currently being evaluated in the Phase II studies for the treatment of Hepatic Tumor.
* Amivantamab: Janssen Research & Development, LLC
Amivantamab is a fully-human EGFR-MET bispecific antibody with immune cell-directing activity that targets tumors with activating and resistance EGFR mutations and MET mutations and amplifications. The drug is based on antibody-dependent cell cytotoxicity mechanism of action. The drug is in Phase II stage of clinical trials for the treatment of Hepatic Tumor.
* Fostroxacitabine bralpamide: Medivir AB
Fostroxacitabine bralpamide is a small molecule a type of smart chemotherapy that delivers the cell-killing compound selectively to the tumor while minimizing the harmful effect on normal cells. being developed by Medivir AB. It works as Nucleotide DNA polymerase inhibitor. The drug candidate is administered through oral route. Currently the drug is being evaluated in Phase I/II for the treatment of Hepatic Tumor.
* ETN101: Etnova Therapeutics Corp.
ETN101 is a synthetic drug candidate designed to be a best-in-class anticancer agent targeting hepatocellular carcinoma. It is being developed with the aim of preoccupying the market for both first-line and follow-up treatments of hepatocellular carcinoma with its high rate of complete remission and safety. It inhibits protein activity using FLT3/KIT/VEGFR2/PDGFRB tyrosine kinase inhibitors and its downstream signaling pathways: PI3K/AKT and RAS-MAPK, working as multiple tyrosine kinase inhibitors (mTKI). The drug is in Phase I stage of clinical trials for the treatment of Hepatic Tumor.
Learn more about Hepatic Tumor Drugs opportunities in our groundbreaking Hepatic Tumor Research and development projects @ Hepatic Tumor Unmet Needs [https://www.delveinsight.com/sample-request/hepatic-tumor-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]
Hepatic Tumor pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration.
* Oral
* Parenteral
* intravenous
* Subcutaneous
* Topical.
Hepatic Tumor Products have been categorized under various Molecule types such as
* Monoclonal Antibody
* Peptides
* Polymer
* Small molecule
* Gene therapy
Discover the latest advancements in Hepatic Tumor Treatment by visiting our website. Stay informed about how we're transforming the future of Oncology @ Hepatic Tumor Market Drivers and Barriers, and Future Perspectives [https://www.delveinsight.com/sample-request/hepatic-tumor-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]
Scope of the Hepatic Tumor Pipeline Report
* Coverage- Global
* Hepatic Tumor Companies- Can Fite Biopharma, MiNA Therapeutics, Medivir AB, Janssen Research & Development, LLC, Etnova Therapeutics Corp., SillaJen Biotherapeutics, Akeso Biopharma, Shanghai Junshi Biosciences, Genmab/Janssen Biotech, Bio-Thera Solutions, Ocuphire Pharma, Surface Oncology, Genoscience, Onyx Pharmaceuticals, Qurient Co., Ltd., Kowa Company, Ltd., Eureka Therapeutics Inc., and others.
* Hepatic Tumor Therapies- Atezolizumab, Bevacizumab 15 mg/kg, Tiragolumab, Zimberelimab, Domvanalimab, and others.
* Hepatic Tumor Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
* Hepatic Tumor Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III
For a detailed overview of our latest research findings and future plans, read the full details of Hepatic Tumor Pipeline on our website @ Hepatic Tumor Drugs and Companies [https://www.delveinsight.com/sample-request/hepatic-tumor-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]
Table of Content
* Introduction
* Executive Summary
* Hepatic Tumor: Overview
* Pipeline Therapeutics
* Therapeutic Assessment
* Late Stage Products (Phase III)
* Comparative Analysis
* Namodenoson: Can Fite Biopharma
* Drug profiles in the detailed report.....
* Mid Stage Products (Phase II)
* MTL CEBPA : MiNA Therapeutics
* Early Stage Products (Phase I)
* Comparative Analysis
* ETN101: Etnova Therapeutics Corp.
* Inactive Products
* Hepatic Tumor Key Companies
* Hepatic Tumor Key Products
* Hepatic Tumor - Unmet Needs
* Hepatic Tumor - Market Drivers and Barriers
* Hepatic Tumor - Future Perspectives and Conclusion
* Hepatic Tumor Analyst Views
* Hepatic Tumor Key Companies
* Appendix
About Us
DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email:Send Email [https://www.abnewswire.com/email_contact_us.php?pr=hepatic-tumor-treatment-drugs-clinical-trials-pipeline-insights-and-companies-2024]
Phone: 9650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Hepatic Tumor Treatment Drugs, Clinical Trials, Pipeline Insights, and Companies 2024 here
News-ID: 3661662 • Views: …
More Releases from ABNewswire
HeroKiddo Unveils Biggest Savings Event: Families Can Save Up to $600 by Combini …
Santa Fe Springs, CA - November 10, 2025 - Hero Kiddo [https://herokiddo.com/] has announced a limited-time savings event that allows buyers to combine discounts on pre-curated inflatable bundles with the company's "no-blower" purchasing option. Taken together, the promotion can yield savings of up to $600, depending on the selected products and configuration.
The event applies across select packages featuring the company's commercial-grade bounce houses, slides, and combo units designed for both…
Fresno Homebuyers are Turning to Narwal Estates Team for Fast, Smart, and Stress …
Image: https://www.abnewswire.com/upload/2025/11/2d033019daefd362b0a204116c5183af.jpg
Fresno, CA - In one of California's most competitive real estate markets, where homes can sell in days and bidding wars are common, the Narwal Estates Team, led by Fresno native and experienced agent Nik Singh, is redefining what it means to buy a home with confidence. Over the past year, the team has guided dozens of families across Fresno, Clovis, and Madera to successful closings, often faster and…
Arashdi Launches Holistic Emotional Healing & Inner Protection Guidance Program …
Arashdi introduces a new emotional healing and inner protection guidance program designed to support individuals navigating stress, emotional imbalance, and personal transformation. The approach focuses on practical self-awareness, grounded inner clarity, and conscious emotional renewal-without religious rituals or complex ceremonial practices.
Image: https://www.abnewswire.com/upload/2025/11/d15ea7f6ca20ae1ef2d9677da0a89d3d.PNG
Arashdi, the spiritual well-being platform known for its personalized guidance services, has announced the launch of its Holistic Emotional Healing & Inner Protection Guidance Program. This new offering is…
BRECO Real Estate Sets a New Standard in Victoria's Property Market - A Trusted …
Melbourne, Victoria - November 10, 2025 - BRECO Real Estate, a premier real estate agency founded by Jas Bhandari, proudly announces its continued growth and success as one of Victoria's most trusted property firms. Built on the foundations of integrity, professionalism, and deep market knowledge, BRECO Real Estate is redefining how property services are delivered across Melbourne's Northern Suburbs and beyond.
With an unwavering commitment to helping clients achieve their property…
More Releases for Hepatic
Top Trends Transforming the Hepatic Encephalopathy Market Landscape in 2025: Inn …
Use code ONLINE30 to get 30% off on global market reports and stay ahead of tariff changes, macro trends, and global economic shifts
What Will the Hepatic Encephalopathy Industry Market Size Be by 2025?
The market size for hepatic encephalopathy has witnessed significant expansion in the past few years. The market, projected to rise from $1.72 billion in 2024 to $1.8 billion in 2025, is estimated to have a compound annual growth…
Top Factor Driving Hepatic Encephalopathy Market Growth in 2025: Rising Prevalen …
What industry-specific factors are fueling the growth of the hepatic encephalopathy market?
The upswing in liver disease incidences is predicted to fuel the hepatic encephalopathy market's expansion. Liver diseases, medical conditions that impact the liver's operation, are treatable with therapies like hepatic encephalopathy which can mitigate symptoms, slow the disease's advancement, boost liver performance, and trim down the recurrence of hepatic encephalopathy by better management of the root causes. This could…
Liver Disease Treatment Market: Advancing Hepatic Care
The liver disease treatment market encompasses a range of medications, therapies, and procedures aimed at managing and curing liver conditions such as hepatitis, fatty liver disease, cirrhosis, liver cancer, and liver failure. Given the liver's critical role in metabolic processes, detoxification, and protein synthesis, effective treatment options are essential for maintaining overall health. The market is influenced by factors such as the rising prevalence of liver diseases, advancements in medical…
Hepatic Encephalopathy Treatment Market - Transforming hepatic encephalopathy ca …
Newark, New Castle, USA: The "Hepatic Encephalopathy Treatment Market" provides a value chain analysis of revenue for the anticipated period from 2023 to 2031. The report will include a full and comprehensive analysis of the business operations of all market leaders in this industry, as well as their in-depth market research, historical market development, and information about their market competitors.
Hepatic Encephalopathy Treatment Market: https://www.growthplusreports.com/report/hepatic-encephalopathy-treatment-market/8818
This latest report researches the industry structure,…
Hepatic Encephalopathy Treatment Market - Driving Progress, Inspiring Hope: Lead …
Newark, New Castle, USA - new report, titled Hepatic Encephalopathy Treatment Market The report has been put together using primary and secondary research methodologies, which offer an accurate and precise understanding of the Hepatic Encephalopathy Treatment market. Analysts have used a top-down and bottom-up approach to evaluate the segments and provide a fair assessment of their impact on the global Hepatic Encephalopathy Treatment market. The report offers an overview of…
Hepatic Biomarkers Market Size & Analysis - Forecast to 2026
The findings reviewed by GME stated that the Global Hepatic Biomarkers Market will grow at a CAGR value of 6.5% from 2021 to 2026. The increasing prevalence of chronic diseases, like cancers and other chronic diseases, is raising the use of hepatic biomarkers all over the world.
Browse 159 Market Data Tables and 119 Figures spread through 189 Pages and in-depth TOC on "Global Hepatic Biomarkers Market - Forecast to 2026"…
